LYRA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

440.00K

+110.53%

-3.757

-53.03%

0.00

-100%

-1.360

-79.08%

0.00

-100%

-1.540

-72.05%

Estimates Revision

The market is revising Upward the revenue expectations for Lyra Therapeutics, Inc. (LYRA) for FY2025, with the revenue forecasts being adjusted by 5.33% over the past three months. During the same period, the stock price has changed by -52.32%.

Revenue Estimates for FY2025

Revise Upward

+5.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-92.23%

In Past 3 Month

Stock Price

Go Down

-52.32%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast LYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYRA is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

16.00

Averages

16.00

High

16.00

Current: 0.000

Low

16.00

Averages

16.00

High

16.00

H.C. Wainwright

Neutral

upgrade

$2 -> $16

2025-06-10

Reason

H.C. Wainwright

Price Target

$2 -> $16

2025-06-10

upgrade

Neutral

Reason

H.C. Wainwright raised the firm's price target on Lyra Therapeutics to $16 from $2 and keeps a Neutral rating on the shares following the company's reverse stock split.

HC Wainwright & Co.

Matthew Caufield

Hold

Reiterates

2025-03-14

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2025-03-14

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Lyra Therapeutics Inc (LYRA.O) is -0.38, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess Lyra Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.08

Current PE

-0.38

Overvalued PE

-0.72

Undervalued PE

-3.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.91

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.38

Undervalued EV/EBITDA

-2.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

85.04

Current PS

5.34

Overvalued PS

173.01

Undervalued PS

-2.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LYRA News & Events

Events Timeline

No data

News

9.5

2025-11-10NASDAQ.COM

Assertio (ASRT) Exceeds Q3 Earnings and Revenue Projections

9.0

2025-09-02Benzinga

Upstream's Innovative Sinus Treatment Reduces Surgical Requirements, Initial Trial Reveals

9.5

2025-08-13NASDAQ.COM

Lyra Therapeutics Posts 85% Q2 Loss Drop

People Also Watch

Frequently Asked Questions

What is Lyra Therapeutics Inc (LYRA) stock price today?

The current price of LYRA is 3.8 USD — it has increased 0 % in the last trading day.

What is Lyra Therapeutics Inc (LYRA)'s business?

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).

What is the price predicton of LYRA Stock?

What is Lyra Therapeutics Inc (LYRA)'s revenue for the last quarter?

Lyra Therapeutics Inc revenue for the last quarter amounts to 25.00K USD, decreased -87.18 % YoY.

What is Lyra Therapeutics Inc (LYRA)'s earnings per share (EPS) for the last quarter?

Lyra Therapeutics Inc. EPS for the last quarter amounts to -3.38 USD, decreased -62.73 % YoY.

What changes have occurred in the market's expectations for Lyra Therapeutics Inc (LYRA)'s fundamentals?

How many employees does Lyra Therapeutics Inc (LYRA). have?

Lyra Therapeutics Inc (LYRA) has 30 emplpoyees as of January 09 2026.

What is Lyra Therapeutics Inc (LYRA) market cap?

Today LYRA has the market capitalization of 6.74M USD.